-
1
-
-
2342591455
-
The discovery of receptor tyrosine kinases: targets for cancer therapy
-
Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004; 4: 361-370.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 361-370
-
-
Gschwind, A.1
Fischer, O.M.2
Ullrich, A.3
-
2
-
-
22044442973
-
Tyrosine kinases as targets for cancer therapy
-
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187.
-
(2005)
N Engl J Med
, vol.353
, pp. 172-187
-
-
Krause, D.S.1
Van Etten, R.A.2
-
4
-
-
0041629450
-
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
-
Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799.
-
(2003)
J Clin Oncol
, vol.21
, pp. 2787-2799
-
-
Mendelsohn, J.1
Baselga, J.2
-
5
-
-
44449127592
-
The epidermal growth factor receptor family: biology driving targeted therapeutics
-
Wieduwilt M, Moasser M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci 2008; 65: 1566-1584.
-
(2008)
Cell Mol Life Sci
, vol.65
, pp. 1566-1584
-
-
Wieduwilt, M.1
Moasser, M.2
-
6
-
-
37049183697
-
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
-
7
-
-
34547871259
-
Targeting HER proteins in cancer therapy and the role of the non-target HER3
-
Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007; 97: 453-457.
-
(2007)
Br J Cancer
, vol.97
, pp. 453-457
-
-
Hsieh, A.C.1
Moasser, M.M.2
-
8
-
-
70349556805
-
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
-
Prickett TD, Agrawal NS, Wei X et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 2009; 41: 1127-1132.
-
(2009)
Nat Genet
, vol.41
, pp. 1127-1132
-
-
Prickett, T.D.1
Agrawal, N.S.2
Wei, X.3
-
9
-
-
0030741967
-
Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma
-
Gilbertson RJ, Perry RH, Kelly PJ et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997; 57: 3272-3280.
-
(1997)
Cancer Res
, vol.57
, pp. 3272-3280
-
-
Gilbertson, R.J.1
Perry, R.H.2
Kelly, P.J.3
-
10
-
-
0030944455
-
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
-
Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997; 16: 1647-1655.
-
(1997)
EMBO J
, vol.16
, pp. 1647-1655
-
-
Graus-Porta, D.1
Beerli, R.R.2
Daly, J.M.3
Hynes, N.E.4
-
11
-
-
33746485766
-
Epidermal growth factor receptor targeting in cancer
-
Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33: 369-385.
-
(2006)
Semin Oncol
, vol.33
, pp. 369-385
-
-
Mendelsohn, J.1
Baselga, J.2
-
12
-
-
18744384721
-
Small molecules with EGFR-TK inhibitor activity
-
Albanell J, Gascon P. Small molecules with EGFR-TK inhibitor activity. Curr Drug Targets 2005; 6: 259-274.
-
(2005)
Curr Drug Targets
, vol.6
, pp. 259-274
-
-
Albanell, J.1
Gascon, P.2
-
13
-
-
33750708563
-
Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling
-
Wong TW, Lee FY, Yu C et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 2006; 12: 6186-6193.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6186-6193
-
-
Wong, T.W.1
Lee, F.Y.2
Yu, C.3
-
14
-
-
38049025794
-
Review: side effects of approved molecular targeted therapies in solid cancers
-
Widakowich C, de Castro G Jr, de Azambuja E et al. Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007; 12: 1443-1455.
-
(2007)
Oncologist
, vol.12
, pp. 1443-1455
-
-
Widakowich, C.1
de Castro Jr., G.2
de Azambuja, E.3
-
15
-
-
22044445517
-
Erlotinib in previously treated non-small-cell lung cancer
-
Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues, P.J.2
Ciuleanu, T.3
-
16
-
-
33748642331
-
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience
-
Guarneri V, Lenihan DJ, Valero V et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006; 24: 4107-4115.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4107-4115
-
-
Guarneri, V.1
Lenihan, D.J.2
Valero, V.3
-
17
-
-
34247480545
-
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
-
Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-344.
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 332-344
-
-
Force, T.1
Krause, D.S.2
Van Etten, R.A.3
-
18
-
-
44649165869
-
Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor
-
Khakoo AY, Kassiotis CM, Tannir N et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008; 112: 2500-2508.
-
(2008)
Cancer
, vol.112
, pp. 2500-2508
-
-
Khakoo, A.Y.1
Kassiotis, C.M.2
Tannir, N.3
-
19
-
-
33748987894
-
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma
-
Rojo F, Tabernero J, Albanell J et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006; 24: 4309-4316.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4309-4316
-
-
Rojo, F.1
Tabernero, J.2
Albanell, J.3
-
20
-
-
17844372539
-
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer
-
Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23: 2445-2459.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2445-2459
-
-
Baselga, J.1
Arteaga, C.L.2
-
21
-
-
33847273041
-
EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences
-
Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol 2007; 62: 53-61.
-
(2007)
Crit Rev Oncol Hematol
, vol.62
, pp. 53-61
-
-
Dassonville, O.1
Bozec, A.2
Fischel, J.L.3
Milano, G.4
-
22
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
-
Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
-
(2004)
N Engl J Med
, vol.351
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
-
23
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
24
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1626-1634
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
-
25
-
-
0035398631
-
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
-
Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-3279.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3267-3279
-
-
Hidalgo, M.1
Siu, L.L.2
Nemunaitis, J.3
-
26
-
-
0036569870
-
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial
-
Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20: 2240-2250.
-
(2002)
J Clin Oncol
, vol.20
, pp. 2240-2250
-
-
Ranson, M.1
Hammond, L.A.2
Ferry, D.3
-
27
-
-
0037106377
-
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial
-
Herbst RS, Maddox AM, Rothenberg ML et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20: 3815-3825.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3815-3825
-
-
Herbst, R.S.1
Maddox, A.M.2
Rothenberg, M.L.3
-
28
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
-
(2006)
N Engl J Med
, vol.355
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
-
29
-
-
20244378677
-
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
-
Agus DB, Gordon MS, Taylor C et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23: 2534-2543.
-
(2005)
J Clin Oncol
, vol.23
, pp. 2534-2543
-
-
Agus, D.B.1
Gordon, M.S.2
Taylor, C.3
-
30
-
-
33646870539
-
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
-
Kollmannsberger C, Schittenhelm M, Honecker F et al. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2006; 17: 1007-1013.
-
(2006)
Ann Oncol
, vol.17
, pp. 1007-1013
-
-
Kollmannsberger, C.1
Schittenhelm, M.2
Honecker, F.3
-
31
-
-
32944461545
-
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
-
Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639.
-
(2006)
Cancer Res
, vol.66
, pp. 1630-1639
-
-
Konecny, G.E.1
Pegram, M.D.2
Venkatesan, N.3
-
32
-
-
51149117030
-
Drug Insight: intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer
-
Cameron DA, Stein S. Drug Insight: intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 2008; 5: 512-520.
-
(2008)
Nat Clin Pract Oncol
, vol.5
, pp. 512-520
-
-
Cameron, D.A.1
Stein, S.2
-
33
-
-
23944476155
-
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
-
Burris HA III, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005; 23: 5305-5313.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5305-5313
-
-
Burris III, H.A.1
Hurwitz, H.I.2
Dees, E.C.3
-
34
-
-
84901290217
-
FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2
-
Ryan Q, Ibrahim A, Cohen MH et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008; 13: 1114-1119.
-
(2008)
Oncologist
, vol.13
, pp. 1114-1119
-
-
Ryan, Q.1
Ibrahim, A.2
Cohen, M.H.3
-
35
-
-
34547470997
-
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
-
Minami Y, Shimamura T, Shah K et al. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 2007; 26: 5023-5027.
-
(2007)
Oncogene
, vol.26
, pp. 5023-5027
-
-
Minami, Y.1
Shimamura, T.2
Shah, K.3
-
36
-
-
33746154236
-
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272
-
Shimamura T, Ji H, Minami Y et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 2006; 66: 6487-6491.
-
(2006)
Cancer Res
, vol.66
, pp. 6487-6491
-
-
Shimamura, T.1
Ji, H.2
Minami, Y.3
-
37
-
-
34347208648
-
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy
-
Li D, Shimamura T, Ji H et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 2007; 12: 81-93.
-
(2007)
Cancer Cell
, vol.12
, pp. 81-93
-
-
Li, D.1
Shimamura, T.2
Ji, H.3
-
38
-
-
34147107009
-
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
-
Sequist LV. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 2007; 12: 325-330.
-
(2007)
Oncologist
, vol.12
, pp. 325-330
-
-
Sequist, L.V.1
-
39
-
-
33751416678
-
HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 1 results in patients with solid tumors
-
Wong KK, Fracasso PM, Bukowski RM et al. HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 1 results in patients with solid tumors. J Clin Oncol (Meeting Abstracts) 2006; 24: 3018.
-
(2006)
J Clin Oncol (Meeting Abstracts)
, vol.24
, pp. 3018
-
-
Wong, K.K.1
Fracasso, P.M.2
Bukowski, R.M.3
-
40
-
-
77954584507
-
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced nonsmall-cell lung cancer
-
Sequist LV, Besse B, Lynch TJ et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced nonsmall-cell lung cancer. J Clin Oncol 2010; 28: 3076-3083.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3076-3083
-
-
Sequist, L.V.1
Besse, B.2
Lynch, T.J.3
-
41
-
-
33751421795
-
A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors
-
Lewis N, Marshall J, Amelsberg A et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) 2006; 24: 3091.
-
(2006)
J Clin Oncol (Meeting Abstracts)
, vol.24
, pp. 3091
-
-
Lewis, N.1
Marshall, J.2
Amelsberg, A.3
-
42
-
-
77957585027
-
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors
-
Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010; 28: 3965-3972.
-
(2010)
J Clin Oncol
, vol.28
, pp. 3965-3972
-
-
Yap, T.A.1
Vidal, L.2
Adam, J.3
-
43
-
-
38049038935
-
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
-
Eskens FA, Mom CH, Planting AS et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008; 98: 80-85.
-
(2008)
Br J Cancer
, vol.98
, pp. 80-85
-
-
Eskens, F.A.1
Mom, C.H.2
Planting, A.S.3
-
44
-
-
78649518887
-
A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2)
-
Yang C, Shih J, Su W et al. A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). J Clin Oncol (Meeting Abstracts) 2010; 28: 7521.
-
(2010)
J Clin Oncol (Meeting Abstracts)
, vol.28
, pp. 7521
-
-
Yang, C.1
Shih, J.2
Su, W.3
-
45
-
-
77954242530
-
Molecular circuits of solid tumors: prognostic and predictive tools for bedside use
-
Ferte C, Andre F, Soria JC. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol 2010; 7: 367-380.
-
(2010)
Nat Rev Clin Oncol
, vol.7
, pp. 367-380
-
-
Ferte, C.1
Andre, F.2
Soria, J.C.3
|